Sensitivity Study of Diagnostic for Detection of Chagas Infection

Determination of Estimated Sensitivity for Chagas Detect Plus Rapid Tests

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02134548

Enrollment

1601

Registered

2014-05-09

Start date

2013-06-30

Completion date

2015-09-30

Last updated

2015-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Diseases

Brief summary

This study is a multi-site trial assessing the sensitivity of Chagas Detect™ Plus rapid test versus standard reference tests (e.g. IFA, IHA, RIPA) for Chagas diagnosis. The Chagas Detect™ Plus rapid test serves as an aid in the clinical laboratory diagnosis of Chagas infection in patients. This test is intended to be used on human whole blood or serum samples. Chagas Detect™ Plus results (positive or negative) must be confirmed by testing with a reference standard test. Subjects will be patients at clinical sites located in Chagas-endemic areas. After informed consent is obtained and the subject is screened for eligibility, 2 diagnostic samples will be collected. One is blood from finger prick, and the other is blood from venous puncture (drawn from vein in arm). Rapid tests and reference tests will be performed by different operators who are laboratory staff members. These staff members, blinded to each other's results, will evaluate the samples from each method independently.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All age groups and both sexes for archive samples, adults only and both sexes for prospective samples. * Samples collected from subjects living in T. cruzi endemic regions. * Information must be available about symptoms, age, and sex of patient from which samples are collected. * The location of sample collection must be recorded.

Exclusion criteria

* Archived samples with linked personal identifiers or any sample for which personal information can be discovered. * Prospective samples from nursing home residents; inmates/subjects in police custody; participants who are unable to understand verbal or written local language in which a certified translation of the informed consent is available, or requires a Legal Authorized Representative (LAR) for consent. * Subject serum specimens that have undergone more than 2 freeze-thaw cycles or that have not been stored frozen.

Design outcomes

Primary

Measure	Time frame
number of subjects with positive result	1 day

Countries

Bolivia, Chile

Outcome results